DrugDashboards

Lidocaine Hydrochloride

Lidocaine Hydrochloride · LIDOCAINE HYDROCHLORIDE 20 mg/mL · Injection · Intravenous · International Medication Systems, Limited

NDC 76329-3390-01 · 10 SYRINGE in 1 PACKAGE / 5 mL in 1 SYRINGE · ANDA · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble. It is in shortage right now — FDA lists the reason as “demand increase for the drug”. One of its named manufacturing plants, International Medication Systems, Ltd., failed FDA inspectionwithin the last two years — the agency’s most serious outcome.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Medicaid spend (2025)

$126,159
10,958 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.6%chance of a new FDA shortage posting for lidocaine hydrochloride (injectable) in the next 90 days

sterile injectable · 4 Class I/II recall(s) in 12 months · OAI inspection at a producing facility (24 months)

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA083173
TE code
AP
Approval date
Jan 1, 1982
Patents / exclusivity
None on file

Shortage history

  • In shortage now — Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)Feb 22, 2012
    Demand increase for the drug
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Lidocaine Hydrochloride (Injection)

LabelerStrengthFirst seenLast seen
B. Braun Medical Inc.LIDOCAINE HYDROCHLORIDE ANHYDROUS 10 mg/mLJul 15, 2026Sep 2, 2026
International Medication Systems, LimitedLIDOCAINE HYDROCHLORIDE 20 mg/mLJul 15, 2026Sep 2, 2026
Medical Purchasing Solutions, LLCLIDOCAINE HYDROCHLORIDE 20 mg/mLJul 15, 2026Sep 2, 2026
Remedyrepack Inc.LIDOCAINE HYDROCHLORIDE 20 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Lidocaine Hydrochloride — NDC 76329-3390-01," retrieved September 3, 2026, https://drugdashboards.com/drug/76329339001.

Free to cite with attribution — see how the data is put together.